Cortexin

Most Common Uses

Cortexin, a polypeptide extract derived from the cerebral cortex of cattle or pigs, is employed primarily in certain countries, particularly in Russia, for its neuroprotective and nootropic properties. It is used to support recovery from neurological conditions, such as traumatic brain injury, stroke, and cerebral ischemia, by promoting neuronal recovery and improving cognitive function. The peptide is also administered to enhance mental performance in cases of cognitive impairment, including memory disorders and age-related cognitive decline.

Cortexin finds application in pediatric neurology to address developmental delays, attention disorders, and speech impairments in children. Its role in reducing oxidative stress and supporting neuronal metabolism makes it a candidate for managing neurodegenerative conditions, though its use remains limited to specific regions due to varying regulatory approvals.

Mechanism of Action

Cortexin exerts its effects through a multifaceted influence on brain function. Composed of low-molecular-weight peptides and amino acids, it promotes neuronal repair and enhances cognitive processes by modulating neurotransmitter activity. The peptide complex facilitates the release of gamma-aminobutyric acid (GABA) and dopamine, which contribute to balanced neuronal signaling and improved synaptic plasticity. Cortexin also supports neuroprotection by reducing oxidative stress and inhibiting inflammatory processes in brain tissue.

Its ability to enhance cerebral metabolism improves energy utilization in neurons, aiding recovery from neurological damage such as that caused by stroke or traumatic brain injury. Cortexin stimulates neurotrophic factors, fostering neuronal growth and survival. These combined actions underpin its use in treating cognitive impairments and neurological disorders, particularly in regions where it is approved for clinical use.

Structure and Pharmacology

Cortexin consists of a mixture of low-molecular-weight peptides and amino acids, with individual components having molecular weights not exceeding 10,000 Da. Unlike single-sequence peptides, Cortexin lacks a defined amino acid sequence due to its heterogeneous composition. This complexity arises from the extraction process, which isolates biologically active peptides and amino acids from cortical tissue. The absence of a specific molecular formula reflects the diverse nature of its constituents, which include neuropeptides and other bioactive molecules. This structural profile contributes to Cortexin’s stability and its ability to interact with various neurological pathways, supporting its therapeutic applications.

Pharmacologically, Cortexin exerts its effects primarily through neuroprotective and neuromodulatory mechanisms, targeting the central nervous system. Administered via intramuscular injection, it enhances neuronal metabolism by improving energy utilization and increasing the synthesis of neurotrophic factors, which support neuronal growth and repair. The peptide complex modulates neurotransmitter activity, particularly by increasing the release of GABA and dopamine, promoting balanced synaptic function and improved cognitive performance.

Cortexin also reduces oxidative stress and inflammation in brain tissue, offering protection against neuronal damage in conditions like stroke, traumatic brain injury, or cognitive impairment. Its pharmacokinetic profile remains less defined due to its complex composition, but its half-life is short, necessitating daily dosing in clinical practice. Cortexin’s ability to cross the blood-brain barrier allows it to directly influence cerebral processes, making it a valuable agent in neurological treatments where approved, such as in Russia and certain other regions.

Dosages

Cortexin is administered through intramuscular injection, primarily in regions like Russia where it is approved for clinical use. For adults, the typical dose ranges from 10 to 20 milligrams (mg) per day, depending on the condition being treated, such as traumatic brain injury, stroke, or cognitive impairment. Treatment courses generally last 5 to 10 days, with daily injections, and may be repeated after a break of one to two months based on medical evaluation.

In pediatric patients, dosages are adjusted according to body weight, commonly 0.5 mg per kilogram, administered once daily for similar treatment durations. Before injection, the lyophilized powder should be dissolved in sterile water or saline, ensuring proper preparation for safe administration. Dosing regimens vary based on patient needs.

Warnings and Cautions

Cortexin requires careful consideration to ensure safe administration. Patients with known hypersensitivity to Cortexin or its components should avoid its use, as allergic reactions, including rash or swelling, may occur, necessitating immediate medical attention. The peptide is not suitable for people with severe kidney or liver dysfunction, as its metabolism and clearance may be affected, potentially leading to adverse effects. Pregnant or breastfeeding women should avoid using Cortexin, as safety data in these populations remain limited.

Pediatric administration, while common for conditions like developmental delays, demands precise weight-based dosing to prevent complications. Mild side effects, such as local irritation at the injection site, may occur, but persistent discomfort warrants medical evaluation. Patients should be carefully monitored during treatment to adjust their dose or discontinue use if unexpected symptoms occur.

Research & Trials

Neuroprotective Effects of Cortexin in Developmental Brain Injury

The study concluded that Cortexin, a preparation of bovine brain cortex polypeptides, demonstrated clear neurotropic and neuroprotective effects in rat models of developmental delay induced by either prenatal ethanol exposure or neonatal hypoxic-ischemic brain injury. Treatment with Cortexin, whether administered intramuscularly or rectally, significantly reduced neurological deficits and improved motor activity, coordination, and sensory-motor performance across multiple behavioral tests. Histological examination further confirmed that Cortexin decreased neuronal damage and preserved a higher proportion of normal neurons compared with placebo. Radiolabeling studies showed that Cortexin polypeptides enter the bloodstream, cross the blood–brain barrier, and distribute into brain tissues effectively through both routes of administration. These findings indicate that Cortexin mitigates neurological impairments and protects brain structure, supporting its therapeutic potential for central nervous system injuries and toxic damage during early development. [1]

Cortexin Improves Cognitive Function in Children

The study concluded that Cortexin is effective and well-tolerated in the treatment of cognitive dysfunction in children aged 3–7 years. Across different groups, including children with ADHD, speech delay, consequences of perinatal CNS lesions, and asthenic/neurotic syndrome, Cortexin significantly improved attention, visual memory, and thinking. The most pronounced effects were observed in younger children (ages 3–4) with ADHD, especially in tasks assessing thinking. Overall, the findings support Cortexin as a beneficial therapy for children with ADHD, speech delay, and perinatal CNS damage, with good tolerability. [2]

Neuroprotective Potential of Cortexin in Brain Ischemia

This study concluded that Cortexin showed strong neuroprotective effects in rodent models of both acute and chronic brain ischemia. Specifically, Cortexin reduced neurological deficits, improved sensorimotor and cognitive functions, enhanced motor coordination and activity, and decreased the size of brain necrosis in acute ischemia. In chronic ischemia, it helped preserve neurons, improved antioxidant defense, and prevented severe neurodegenerative changes. Importantly, radioactively labeled Cortexin was shown to cross the blood–brain barrier effectively, and receptor binding assays indicated that its actions are likely mediated through glutamatergic (AMPA, kainate, mGluR1, mGluR5) and GABAergic (GABAA1) mechanisms. Overall, Cortexin, at therapeutic doses, was as effective as Cerebrolysin and superior to Actovegin in many measures, supporting its role as a promising neuroprotective therapy in ischemic brain injury. [3]